Cargando...
Enzalutamide for patients with metastatic castration-resistant prostate cancer
OBJECTIVE: To review and evaluate current literature on the US Food and Drug Administration (FDA)-approved drug enzalutamide (XTANDI(®)) in metastatic castration-resistant prostate cancer. DATA SOURCES: Literature search was done through PubMed using the terms enzalutamide, MDV3100, abiraterone, and...
Guardado en:
| Publicado en: | Onco Targets Ther |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4407758/ https://ncbi.nlm.nih.gov/pubmed/25945058 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S80488 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|